STOCKHOLM, 19 August 2020: Today, Lipidor AB publishes its interim report for the period July – September 2020. The quarterly report is available on the company's website lipidor.se (https://lipidor.se/investors/financial-reports/interim-reports/) and in the attached pdf. Summary of the interim report – third quarter 2020 A quarter of high activity and many important milestones, including: a directed share […]
Stockholm, 1 October 2020: Lipidor AB (Nasdaq First North: LIPI) today announces that the company is strengthening its management team through the recruitment of Anders Hagman as Chief Development Officer. Hagman will assume the role as of 1 October 2020. Lipidor's growth journey continues, and the completion of the management team is a key step […]
Stockholm, 30 September 2020 – Lipidor AB (Nasdaq First North:LIPI) today announces a positive outcome of the feasibility study into the development of topical medicinal cannabis products for the treatment of skin inflammations and psoriatic lesions. The study was conducted in collaboration with Cannassure Therapeutics Ltd. (TASE:CSURE), an Israeli company specializing in the development and […]
In the last press release, Lipidor published that the information and interim report was such that Lipidor is required to publish under the EU Market Abuse Regulation. This was incorrect as the interim report for H1 2020 contains no insider information. This has been corrected in this press release. Today, Lipidor AB publishes its interim […]
Today, Lipidor AB publishes its interim report for the period January – June 2020. The quarterly report is available on the company's website lipidor.se (https://lipidor.se/investors/financial-reports/interim-reports/) and in the attached pdf. Summary of the interim report – second quarter 2020 Lipidor has continuous positive ongoing out-licensing discussions with potential licensees. Preperations for initiation of the phase lll-study […]
Today, 11 August 2020, Lipidor AB (publ) (the “Company” or “Lipidor”) held an extraordinary general meeting (“EGM”) in Solna, Sweden. The EGM resolved upon, inter alia, the following resolutions. Resolution on approval of the Company’s subsidiary Emollivet AB’s (the “Subsidiary” or “Emollivet”) resolution on a new issue of shares The EGM resolved unanimously to approve […]
Lipidor AB (Nasdaq First North: LIPI) today announced an agreement with Cadila Pharmaceuticals, a leading Indian pharmaceutical company with extensive CRO capacity, to conduct a Phase III study for Lipidor's drug candidate AKP-02. The study is expected to commence in Q1 2021 with final reporting in Q1 2022. AKP-02 is an antipsoriasis medicine that combines […]
Lipidor AB ("Lipidor") today announces that the subsidiary Emollivet AB ("Emollivet") has recruited Stina Linge as CEO. Stina Linge joins Emollivet from her most recent role as Head of Startup Programs at Chalmers Ventures. Stina will take up her position on September 2, 2020. Lipidor recently announced an updated plan to increase the rate of […]
The shareholders of Lipidor AB (publ) (the "Company") are hereby invited to attend an Extraordinary General Meeting on August 11, 2020 at 11:00 a.m. CET. 13.00 at Karolinska Institutet Science Park, Fogdevreten 2 in Solna. Voting rights registration begins at 12.30 p.m. and will cease when the meeting is opened. The Company continues to closely […]
Lipidor AB ("Lipidor" or the “Company") and its subsidiary Emollivet AB ("Emollivet") have formalized the relationship by entering into a licence agreement that regulates the right to Lipidor's patented AKVANO® technology. On June 30, Emollivet's Extraordinary General Meeting resolved on a directed new share issue of SEK 4 million, conditional on the approval of Lipidor's […]